ユーザーIDをお忘れですか? or パスワードをお忘れですか?

東京ビッグサイト | 有明

2018年11月11日 (日) 午前 9:30 - 2018年11月13日 (火) 午後 5:40

〒135-0063, 東京都江東区有明3-11-1



[V3-S5] Chance and Challenge to Maximize Product Value - Key Findings from Collaboration Between Medicine Development Division and Medical Affairs Division -

Session Chair(s)

Hiroshi  Aino, MD, PhD

Hiroshi Aino, MD, PhD

Senior Medical Officer

Sumitomo Dainippon Pharma Co., Ltd., Japan

Aiming to maximize product value seamlessly from the medicine development stage to launch stage, some pharmaceutical companies are creating or implementing key strategies such as development strategy, publication strategy, KOL engagement strategy etc with more closer partnership between medicine development related division and medical affairs division. Also, Medical Science Liaisons (MSLs) play key role which collects unmet medical needs from healthcare professionals and their contribution would be crucial one to find new development opportunity or to generate valuable evidence. In this session, presenters will provide some examples of collaboration in each company and we are going to discuss how medicine development division and medical affairs division should collaborate to maximize product value.


Yasuyuki  Katayama, MD, PhD

Chance and Challenge to Maximize Product Value

Yasuyuki Katayama, MD, PhD

Pfizer Japan Inc., Japan

Corporate Officer, Country Medical Director and Head of Medical Japan

Sotaro  Enatsu, MD, PhD

Chance and Challenge to Maximize Product Value

Sotaro Enatsu, MD, PhD

Eli Lilly Japan K.K., Japan

Manabu  Murakami, PhD, MS, RPh

Collaboration between Medical Information and Clinical Pharmacology

Manabu Murakami, PhD, MS, RPh

Astellas Pharma Inc., Japan

Vice President, Clinical Pharmacology Development

Kosuke  Kozaiwa, MD

Kosuke Kozaiwa, MD

GlaxoSmithKline K.K., Japan

VP & Vice Head, Japan Development